SAN DIEGO, Jan. 29, 2018 /PRNewswire/ -- Aethlon Medical,
Inc. (Nasdaq: AEMD), a therapeutic technology company focused on
unmet needs in global health and biodefense today announced it will
issue third quarter results for the fiscal year ended March 31, 2018 at 4:15 pm
eastern time on Thursday, February 1, 2018.
Management will host a conference call on Thursday, February 1, 2018 at 4:30 pm eastern time to review financial results
and corporate highlights. Following management's formal remarks,
there will be a question and answer session.
To listen to the call by phone, interested parties within the
U.S. should call 1-844-836-8741 and
International callers should call 1-412-317-5442. All callers
should ask for the Aethlon Medical Inc., conference call. The
conference call will also be available through a live webcast at
www.aethlonmedical.com. Details for the webcast may be found on the
Company's IR events page at http://ir.aethlonmedical.com.
A replay of the call will be available approximately one hour
after the end of the call through February
8, 2018. The replay can be accessed via Aethlon Medical's
website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088
(international) or Canada Toll Free at 1-855-669-9658. The replay
conference ID number is 10116549.
About Aethlon Medical, Inc.
Aethlon Medical is focused on addressing unmet needs in global
health and biodefense. The Aethlon Hemopurifier® is a
first-in-class therapeutic device designed to address
life-threatening viral infections. The United States Food and
Drug Administration (FDA) has designated the Hemopurifier® as a
Breakthrough Device related to the treatment of life-threatening
viruses that are not addressed with approved therapies.
In collaboration with leading government and non-government
research institutes, Aethlon has validated the ability of the
Hemopurifier® to capture a broad-spectrum of pandemic influenza
viruses, mosquito-borne viruses and deadly hemorrhagic
viruses. Based on its use to treat Ebola virus, the
Hemopurifier® was named a "Top 25 Invention" and one of the "Eleven
Most Remarkable Advances in Healthcare," by TIME Magazine.
Aethlon is also investigating the potential therapeutic use of
the Hemopurifier® to reduce the presence of tumor-derived exosomes,
which contribute to immune-suppression and the spread of metastasis
in cancer patients. Additionally, Aethlon is the majority
owner of Exosome Sciences, Inc. (ESI), which is focused on the
discovery of exosomal biomarkers to diagnose and monitor cancer and
neurological disorders, including Alzheimer's disease (AD) and
Chronic Traumatic Encephalopathy (CTE). Additional
information can be found online at www.AethlonMedical.com and
www.ExosomeSciences.com. You can also connect with us on
Twitter, LinkedIn, Facebook and Google+.
Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-459-7800 extension 3300
Jfrakes@aethlonmedical.com
Investor Relations:
John Marco
CORE IR
516 222 2560
johnm@coreir.com
View original
content:http://www.prnewswire.com/news-releases/aethlon-medical-to-release-third-quarter-fiscal-year-2018-financial-results-and-host-conference-call-on-february-1-2018-300588950.html
SOURCE Aethlon Medical, Inc.